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Abstract
The objective of this work is to analyze the survival of infliximab,
etanercept and adalimumab in patients who have switched
among tumor necrosis factor (TNF) antagonists for the
treatment of chronic arthritis. BIOBADASER is a national
registry of patients with different forms of chronic arthritis who
are treated with biologics. Using this registry, we have analyzed
patient switching of TNF antagonists. The cumulative
discontinuation rate was calculated using the actuarial method.
The log-rank test was used to compare survival curves, and Cox
regression models were used to assess independent factors
associated with discontinuing medication. Between February
2000 and September 2004, 4,706 patients were registered in
BIOBADASER, of whom 68% had rheumatoid arthritis, 11%
ankylosing spondylitis, 10% psoriatic arthritis, and 11% other
forms of chronic arthritis. One- and two-year drug survival rates
of the TNF antagonist were 0.83 and 0.75, respectively. There
were 488 patients treated with more than one TNF antagonist.
In this situation, survival of the second TNF antagonist
decreased to 0.68 and 0.60 at 1 and 2 years, respectively.
Survival was better in patients replacing the first TNF antagonist
because of adverse events (hazard ratio (HR) for discontinuation
0.55 (95% confidence interval (CI), 0.34–0.84)), and worse in
patients older than 60 years (HR 1.10 (95% CI 0.97–2.49)) or
who were treated with infliximab (HR 3.22 (95% CI 2.13–4.87)).
In summary, in patients who require continuous therapy and
have failed to respond to a TNF antagonist, replacement with a
different TNF antagonist may be of use under certain situations.
This issue will deserve continuous reassessment with the arrival
of new medications.
Introduction
When initiated early in rheumatoid arthritis (RA), significant
control of joint inflammation and damage and improvement in
physical function are obtained with disease modifying
antirheumatic drugs (DMARDs), alone or in combination with
tumor necrosis factor (TNF) antagonists [1]. Three TNF antag-
onists, infliximab, etanercept, and adalimumab, have demon-
strated efficacy in RA [2-4] and are commercially available.
The World Health Organization Collaborating Center consen-
sus proposed that RA patients with active disease who have
failed to respond to an adequate course of DMARDs are eligi-
ble for anti-cytokine therapy [5]. Other guidelines recommend
a similar indication for these agents. In other forms of chronic
arthritis, TNF antagonists are also recommended for patients
whose disease does not respond to non-steroidal anti-inflam-
matory drugs or DMARDs [6-9].
In RA, evidence based on clinical trials suggests that these
three drugs are equally effective, though they have distinct
structural, pharmacokinetic, and pharmacological properties
[10], and differences in their modes of action [11]. Compara-
ble effectiveness has also been found in clinical settings [12].
Nevertheless, a proportion of patients do not benefit from
treatment with a certain TNF antagonist, and thus the use of a
second antagonist when the first has failed is advocated
based on a few clinical reports of small numbers of patients
[13-16]. For the other forms of chronic arthritis, this informa-
tion is still lacking; whether a second TNF antagonist would be
effective is a relevant clinical question.
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In February 2000, the Spanish Society of Rheumatology
(SER) launched a registry (Base de Datos de Productos
Biológicos de la Sociedad Española de Reumatología
(BIOBADASER)) for patients with rheumatic conditions
treated with biologics, including TNF antagonists. Over the
last four and half years, 4,706 patients from 95 hospitals have
been included in this registry and have been actively followed.
Although the emphasis of the registry is drug safety, informa-
tion on discontinuation of TNF antagonists for any cause is
gathered as well. In the present study, we analyze the drug sur-
vival rates of TNF antagonists, as a surrogate for their effec-
tiveness, in 488 patients with rheumatic diseases who had
switched from one TNF antagonist to another.
Materials and methods
BIOBADASER methodology has been described previously
[17] and is detailed the BIOBADASER website [18]. Briefly,
BIOBADASER is a registry established in February 2000 for
the active long-term follow-up and assessment of the safety of
biological response modifiers in rheumatic patients. The regis-
try, which is supported by the SER and funded, in part, by the
Spanish Agency for Medicines and Medical Devices, notes rel-
evant adverse events occurring during and after treatment.
Patients registered in BIOBADASER are those with rheumatic
diseases being treated with any of the approved biological
response modifiers in the participating centers; participation is
voluntary. Infliximab was made available for clinical use in
August 1999, etanercept in April 2003 and adalimumab in
September 2003 (some patients actually started on adalimu-
mab before general availability, as part of a clinical study, and
their data were entered in BIOBADASER once the study
ended as all relevant variables had been collected properly).
SER guidelines do not propose molecule-specific criteria for
prescribing any of the TNF inhibitors.
Data collected systematically include gender, date of birth,
diagnosis, date of diagnosis, treatment type, and dates of
commencement and of discontinuation. Should a patient dis-
continue the treatment, the main reason for stopping is also
recorded (inefficacy, adverse event, or other causes). When a
patient has a relevant adverse event, additional data are regis-
tered, including the date of occurrence, type and classification
of event, outcome, concomitant treatment, and co-morbidity.
The quality of our database is assured by a clear definition of
its aim, an optimized number of variables, and an easy method
of data collection that allows consistency checks. Incomplete-
ness and agreement of data with patient charts are assessed
in site by annual audits of 10% of all patients registered. All
errors are corrected accordingly following these audits, yield-
ing an expected underreporting of 11% of actual discontinua-
tions or adverse events. Data from centers in which there is
proved incompleteness of data are censored at the time of the
last reliable information. The registry was approved by the
Spanish Medicines Agency (Ministerio de Sanidad y Con-
sumo), and the information regarding patients was gathered in
the registry according to the present official regulations on
data protection. The number of patients receiving biologics for
rheumatic diseases registered in BIOBADASER represents
around 60% of the total population treated in Spain.
Statistical methods
The cumulative rate of discontinuation was calculated using
the actuarial method with multiple-failure per patient. Survival
curves in figures are presented with patients starting each time
interval, but not with failures, data which are included in the
survival estimates for simplicity. The time of starting the TNF
antagonist was time 0. The log-rank test was used to compare
survival curves, and Cox regression models were used to
assess the difference between groups and to measure asso-
ciation with risk factors for discontinuation. The variables
included in the Cox models for discontinuation of first treat-
ment were sex, age group, TNF-antagonist, year of first treat-
ment with a TNF-antagonist, and diagnosis (RA, ankylosing
spondylitis, psoriatic arthritis, juvenile idiopathic arthritis, or
others). The variables included in the Cox models for discon-
tinuation of the second treatment were the same plus the main
reason of discontinuation of the first treatment. The bivariate
models included primarily only the dependent variable and one
independent variable at a time. Subsequently, all variables
reaching a p value < 0.10 were included in multivariate models
to assess independent associations and better ascertain inter-
actions between variables. Additionally, we wanted to identify
the characteristics of patients with longer survival of the sec-
ond course of treatment (more than one year). For this analysis
we used logistic regression, bivariate and multivariate analy-
ses, in which the dependent variable was long duration of the
second treatment and the explanatory variables those listed
above.
Results
A total of 3,130 women and 1,576 men using TNF antagonists
with an overall age of 50 ± 15 years (mean ± standard devia-
tion) were registered in BIOBADASER from the starting date
in February 2000 until September 2004. Diagnoses were
68% RA, 11% ankylosing spondylitis, 10% psoriatic arthritis,
and the remaining 11% a variety of other chronic inflammatory
rheumatic conditions. There was a total of 5,263 treatments
with TNF antagonists, and 1,221 discontinuations. The rea-
sons for discontinuation were adverse events in 562 (46%),
inefficacy in 465 (38%), patients' decision in 86 (7%), physi-
cians' decision in 38 (3%), improvement in 14 (1%), preg-
nancy in 10 (1%), poor vein access in 8 (1%), and renal failure
secondary to previously known amyloidosis in 3 (0.5%). Fif-
teen patients were lost to follow up. A total of 488 patients
were treated with more than one TNF antagonist (441 patients
with two, and 47 with at least three), of whom 385 had RA.
The total exposure rate was 9,269 patient years: 7,109 patient
years for infliximab, 1,863 patient years for etanercept, and
295 patient years for adalimumab.Available online http://arthritis-research.com/content/8/1/R29
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Drug survival at first year of treatment depended not only on
whether it was the first or successive treatment (Figure 1), but
also on the agent used. In this sense, survival of the first TNF
antagonist after one year of treatment was slightly lower, but
statistically significant, for infliximab (0.81 (range 0.79 to
0.82)) compared to etanercept (0.88 (0.85 to 0.91)) and adal-
imumab (0.87 (0.82 to 0.91)). The drug survival is consistently
lower when the drugs are used as a second treatment, and
statistically lower for infliximab (0.34 (0.19 to 0.51)) than for
etanercept (0.76 (0.68 to 0.81)) or adalimumab (0.67 (0.42 to
0.83)). However, infliximab treatments were first started 40
and 50 months before any etanercept and adalimumab treat-
ments, respectively. A similar trend was seen for the third TNF
antagonist used, but the numbers were too small for a mean-
ingful analysis.
Reasons for discontinuation of the three TNF antagonists were
similar (Table 1); adverse events were the most frequent rea-
son (48%) for discontinuing the agent used in the first place.
The kappa value for concordance between the reasons for dis-
continuation of the first versus the second treatment was 0.29.
Survival of the second TNF antagonist was better (p = 0.007)
if the first one was replaced because of an adverse event (Fig-
ure 2).
Replacement of infliximab by etanercept
There were 356 patients switched from infliximab to etaner-
cept. The first year survival of etanercept was 0.78 (95% con-
fidence interval (CI): 0.71–0.83). The median treatment
duration to discontinuation of infliximab was 0.56 (P25–75:
0.46–0.68) years, and of etanercept 0.24 (P25–75: 0.16–0.34)
years (p < 0.001). There were no statistical differences in the
reasons for discontinuing infliximab or etanercept; these were
inefficacy in 57% of the cases and adverse events in 42%.
Replacement of etanercept by infliximab
Fifty-two patients who failed to respond to etanercept as the
first TNF antagonist received infliximab. First year survival of
infliximab was 0.28 (95% CI: 0.15–0.42). The median treat-
ment duration to discontinuation of etanercept was 0.51 (95%
CI: 0.19–0.84) years, and of infliximab 0.51 (95% CI: 0.19–
0.66) years. There were differences, however, in the reasons
for discontinuing etanercept and infliximab. Etanercept was
discontinued in 82% of the cases because of inefficacy, and
infliximab was discontinued due to adverse events in 54% of
cases (χ2 p = 0.015).
Replacement of infliximab by adalimumab
Thirty-three patients switched from infliximab to adalimumab.
First-year survival of adalimumab was 0.69 (95% CI: 0.43–
0.85). The median treatment duration to discontinuation of inf-
liximab was 0.73 (95% CI: 0.04–0.95) years, and this duration
was 0.18 (95% CI: 0.12) years for adalimumab. The reasons
for discontinuation were similar for the two agents.
Replacement of etanercept by adalimumab
Only 14 patients switched from etanercept to adalimumab, of
whom two had discontinued as of analysis day. First year sur-
vival of adalimumab was 0.75 (95% CI: 0.31–0.93). The
median treatment duration to discontinuation of etanercept
was 0.55 (95% CI: 0.23–1.29) years, and 0.06 (no 95% CI
available) years for adalimumab (p = 0.003). Reasons for dis-
continuation were similar for etanercept and adalimumab.
Figure 1
Survival curve of tumor necrosis factor (TNF) antagonists in BIOBA- DASER during the first two years of use, ranked by order of treatment Survival curve of tumor necrosis factor (TNF) antagonists in BIOBA-
DASER during the first two years of use, ranked by order of treatment. 
The numbers under the curves represent the patients known to be still 
on treatment by the end of the interval. Differences in the number 
between intervals do not mean that patients failed (stopped TNF antag-
onist). They actually represent the patients known to be still on treat-
ment as of the time marked.
Figure 2
Survival of the second tumor necrosis factor (TNF) antagonist depend- ing on the reason of replacement of first treatment Survival of the second tumor necrosis factor (TNF) antagonist depend-
ing on the reason of replacement of first treatment. The numbers under 
the curves represent the patients known to be still on treatment by the 
end of the interval. Differences in the number between intervals do not 
mean that patients failed (stopped TNF antagonist). They actually repre-
sent the patients known to be still on treatment as of the time marked. 
AE, adverse effect.Arthritis Research & Therapy    Vol 8 No 1    Gomez-Reino et al.
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Risk factors for discontinuation and factors associated 
with a prolonged second course of treatment
There are no clear differences in the survival of the second
TNF antagonist among patients with different diagnosis,
although there seems to be a trend toward worse survival in
the second trial of a TNF antagonist in RA, and even more in
juvenile idiopathic arthritis (Table 2).
There are also no differences in survival at one year depending
on the year of start of the first TNF antagonist: 84% in year
2000, 82% in year 2001, 81% in year 2002, and 83% in year
2003. According to the results of the bivariate Cox regression
models, the factors with the strongest association with discon-
tinuation of the first treatment were therapy with infliximab
(hazard ratio (HR) 1.50 (95% CI: 1.27–1.77)) and a diagnosis
of RA (HR 1.36 (95% CI: 1.18–1.56)). We did not find any
interaction between diagnosis and individual TNF antagonist.
Being older than 60 (HR 1.21 (95% CI: 1.07–1.38)) and
female (HR 1.25 (95% CI: 1.10–1.43)) were not independ-
ently associated with discontinuation, as demonstrated by the
introduction of the diagnosis of RA in the models. Infliximab
has the strongest association with discontinuation of the sec-
ond treatment (HR 3.83 (95% CI: 2.58–5.68)). Having sus-
pended the first treatment as a consequence of adverse
events reduced the probability of discontinuation of the sec-
ond treatment by half (HR 0.54 (95% CI: 0.34–0.84)).
Discussion
In this study, we analyzed drug survival in patients switching
TNF antagonists for chronic arthritis. Overall, our results show
that the probability of retaining a second TNF antagonist is
lower than that of retaining the first one. Of further interest,
Table 1
Rate of discontinuation of three tumor necrosis factor antagonists; reasons for discontinuation and rank of treatment
TNF antagonist Reason for discontinuation Rate per 100 patient years exposed
First treatment Second treatment
Infliximab Adverse events 6.5 32.7
Lack of efficacy 4.7 38.5
Etanercept Adverse events 3.8 6.1
Lack of efficacy 3.6 9.3
Adalimumab Adverse events 7.2 12.5
Lack of efficacy 3.2 12.5
TNF, tumor necrosis factor.
Table 2
One year drug survival of first and second tumor necrosis factor antagonist, by diagnosis
Diagnosis Rank of treatment Number starting Number failed Survival (95% CI)
Rheumatoid arthritis First 2,235 518 0.83 (0.82–0.84)
Second 194 72 0.79 (0.74–0.83)
Ankylosing spondylitis First 300 49 0.89 (0.86–0.92)
Second 8 1 0.95 (0.72–0.99)
Psoriatic arthritis First 289 55 0.87 (0.83–0.90)
Second 15 8 0.81 (0.65–0.90)
Juvenile idiopathic arthritis First 126 16 0.90 (0.84–0.94)
Second 7 7 0.49 (0.22–0.72)
All differences between survival curves in first and second treatment for each diagnosis have a p > 0.001.Available online http://arthritis-research.com/content/8/1/R29
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probability of survival was influenced by diagnosis, reason for
drug replacement, and perhaps the molecule used.
Measuring the effectiveness of drugs through observational
databases has some limitations, such as assignment of treat-
ment, patient selection bias, and the absence of a washout
period [19]. Nonetheless, drug survival can be taken as a sen-
sible indicator of its effectiveness in the clinical setting, and
community-based studies that analyze continuation of treat-
ment with different DMARDs are common in rheumatology
[20-25]. Furthermore, withdrawal rates of DMARDs in obser-
vational studies are similar to those reported in clinical trials
[25]. This type of analysis may also demonstrate the effective-
ness of new therapies [26].
In a study of RA conducted in seven Swedish clinical centers,
discontinuation rates at 24 months of infliximab and etaner-
cept were 25% and 21%, respectively, in agreement with our
results [12]. This observation is in contrast with the 0% dis-
continuation rate reported after 15 months of treatment with
infliximab and etanercept in a university clinic in the USA [27].
Parameters other than efficacy and safety, such as co-morbid-
ity, co-medications [28], costs, availability of other therapies,
patients' and physicians' expectations, and adherence to treat-
ment [29], are at play. Adherence is also important in this type
of analysis. It is a reflection, among other elements, of the
patient's compliance [26], pertinent in the case of molecules
with different modes of administration, and of variable costs in
the diverse health systems. Whether all these factors explain
the dissimilarity in the drug survival of TNF antagonists needs
further elucidation. Of note, TNF antagonists have similar sur-
vival in the different forms of chronic arthritis.
In a previous study, improvement was reported in 8 of 14 RA
patients who switched from infliximab to etanercept or from
etanercept to infliximab (6 patients) because of adverse events
or lack of efficacy [13]. In another study, improvement was
observed in 20 patients replacing etanercept with infliximab
[14]. The efficacy and safety of four infusions of infliximab in
patients failing to respond to etanercept have been described
as well [15]. Finally, improvement in inflammation parameters
was seen in 12 of 14 patients switching from infliximab to
etanercept in another recent study [16]. Information regarding
switching to or from adalimumab is not available yet. In the
present study, efficacy based on evaluation of clinical parame-
ters was not investigated. Instead, effectiveness was
assessed as the probability of drug survival in a large number
of patients. Our results indicate that switching TNF antago-
nists may be effective in a selected group of patients.
Older age emerged as a predictor of shortened drug survival.
This is not surprising in light of older patients' recognized risk
of suffering medication-related problems [29].
Unexplained is the lower survival of infliximab when compared
to other TNF antagonists, especially when used for replace-
ment therapy. Bias towards the use of new drugs in the most
severe or non-responder patients [30] distorts assessment of
efficacy. This bias disappears as the pool of patients com-
pletes the exposure to the new agent [31]. It should be kept in
mind that infliximab treatment was started 40 and 50 months
before etanercept and adalimumab, respectively. When inflixi-
mab was made available, it was first used in the most severe
cases, in those patients in whom good drug survival was not
very much expected. As other TNF antagonists became avail-
able, patients with a less severe disease were offered these
treatments, thus improving overall drug survival (Figure 3). In
addition, availability of other TNF antagonists may have led to
early drug discontinuation and replacement with a novel agent.
In all probability, discontinuation rates of the new TNF antago-
nists in clinical practice will increase with the arrival of other
therapeutic agents. Also, a key variable among the members
of the TNF antagonist class is the route of administration [32].
Infusion reaction occurs early in the follow-up of patients with
infliximab, which cuts the drug survival dramatically, especially
if taking into account that, in this case, the initiation and dis-
continuation date are the same, something very unusual with
other preparations. Furthermore, the intravenous route is gen-
erally related to more adverse events. Also, patients may have
preferences for particular routes, for example, subcutaneous,
and so ask the physician for a change, although this was the
main reason for discontinuation in only four cases.
In our study, in contrast with others, differences in cost were
not a major consideration for using one or another TNF antag-
onist, because of the free, unrestricted access to the drugs,
provided to all patients by the National Health System.
Figure 3
Survival estimates of infliximab before and after the marketing authoriza- tion of etanercept (p < 0.001) Survival estimates of infliximab before and after the marketing authoriza-
tion of etanercept (p < 0.001).Arthritis Research & Therapy    Vol 8 No 1    Gomez-Reino et al.
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Conclusion
Our study supports the replacement of TNF antagonists in a
select group of patients with chronic arthropathies who
require continuous therapy. Considering the arrival of new
medications, this issue will deserve reassessment because of
greater expectancies of patients and doctors.
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de l'Esperança y del Mar); Víctor Eliseo Quevedo Vila (Hospital Comar-
cal de Monforte); Javier Rivera Redondo, Teresa González Hernández 
(Instituto Provincial de Rehabilitación); José Manuel Rodríguez Heredia, 
Ángel Gallegos Cid, Jesús García Arroba Muñoz, Miguel Cantalejo 
Moreira (Hospital Universitario de Getafe); Raquel Almodovar, Javier 
Quiros Donate, Pedro Zarco Montejo, Ramón Mazzucchelli (Hospital 
Fundación Alcorcón); Alfonso Corrales Martínez (Hospital Comarcal de 
Laredo); Dolors Boquet Estruch (Hospital Arnau de Vilanova); Francisco 
Pérez Torres (Hospital General de Requena); José Ivorra Cortes (Hos-
pital Gral de Onteniente); Xavier Suris Armangue (Hospital General de 
Granollers); Trinidad Pérez Sandoval (Hospital Virgen Blanca); Javier 
Calvo Catalá, Cristina Campos (Hospital General Universitario de 
Valencia); Maria Francisca Pina Pérez (Hospital Rafael Méndez); Cris-
tina Hidalgo Calleja (Hospital de La Santísima Trinidad); Julia García Available online http://arthritis-research.com/content/8/1/R29
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Consuegra, Rosa Merino Muñoz (Hospital Infantil La Paz); Miquel Sala 
Gómez (Hospital de Figueres); Montserrat Centellas (Hospital de 
Mataró); José Miguel Ruiz Martín (Hospital de Viladecans); Antonio Juan 
Mas, Inmaculada Ros Vilamajó (Fundación Hospital Son Llàtzer); Jaime 
Fernández Campillo, Rocío González Molina (Hospital del SVS Vega 
Baja); Mauricio Minguez Vega, Gaspar Panadero Tendero (Hospital San 
Juan de Alicante); Jesús Ibáñez Ruan (Policlínico Vigo, SA (Povisa)); 
Anna Martínez Cristobal, Pilar Trenor (Hospital de La Ribera); Jenaro 
Graña Gil (Hospital Santa Teresa); Ma Teresa Bosque Peralta (Hospital 
Clínico Universitario Lozano Blesa); Ana Urruticoechea Arana (Hospital 
Can Misses de Ibiza); José Román Ivorra, Inmaculada Chalmeta (Hospi-
tal Universitario Dr Peset); Javier Alegre López, Bonifacio Álvarez Lario, 
José Luis Alonso Valdivielso, Julia Fernández Melón (Hospital General 
Yagüe); Ma Angeles Belmonte López (Clínica A Belmonte); Dolores 
Montero* (Agencia Española del Medicamento y Productos Sanitarios); 
Loreto Carmona* (Sociedad Española de Reumatología).
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